Clinical trial
A Phase 2a Open Label Study of the Safety and Efficacy of a Single Dose of Weekly Chloroquine (CQ) and Azithromycin (AZ) Administered in Combination for Malaria Prophylaxis in Healthy Adults Challenged With 7G8 Chloroquine-Resistant Plasmodium Falciparum in a Controlled Human Malaria Infection (CHMI) Model
NCT03278808 is registered in ClinicalTrials.gov with U.S. Army Medical Research and Development Command as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Open Label Study of the Safety and Efficacy of a Single Dose of Weekly Chloroquine (CQ) and Azithromycin (AZ) Administered in Combination for Malaria Prophylaxis in Healthy Adults Challenged With 7G8 Chloroquine-Resistant Plasmodium Falciparum in a Controlled Human Malaria Infection (CHMI) Model
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- September 17, 2018
- Completion date
- January 1, 2020
- Enrollment
- 0 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.